This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ligand Pharmaceuticals Inc (LGND)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 11.42M -527.00K 10.18M -10.37M
Operating Gains/Losses 5.00K -17.00K 6.00K -607.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 2.37M 1.52M -3.92M -375.00K
(Increase) Decrease in Inventories 646.00K 1.03M 1.11M 0.00
(Increase) Decrease In Other Current Assets -130.00K 515.00K 4.86M -3.93M
(Decrease) Increase In Payables -2.76M -4.80M -11.57M -13.45M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital -827.00K -1.03M 3.63M -6.98M
Other Non-Cash Items 7.16M 2.85M 6.69M 7.90M
Net Cash From Continuing Operations 21.33M 1.06M -1.17M -27.31M
Net Cash From Discontinued Operations -642.00K -900.00K 0.00 240.00K
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 20.69M 161.00K -1.17M -27.07M
Sale of Property, Plant & Equipment 3.00K 20.00K 530.00K 589.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 10.00M 19.35M 54.04M
Purchases of Property, Plant & Equipment -3.95M -595.00K -78.00K -70.00K
Acquisitions 0.00 0.00 -32.02M -2.83M
Purchases of Short-Term Investments 0.00 0.00 -10.00M -35.58M
Other Cash from Investing Activities -1.03M -8.16M -2.91M -1.60M
Cash Provided by Financing Activities
Net Cash From Investing Activities -4.97M 1.26M -25.13M 14.54M
Issuance of Debt 0.00 7.50M 30.00M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 2.97M 6.29M 54.00K 23.00K
Repayment of Long-Term Debt -19.59M -10.00M 0.00 -91.00K
Repurchase of Capital Stock 0.00 0.00 -55.00K -91.00K
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 154.00K 124.00K 0.00 0.00
Net Cash From Financing Activities -16.46M 3.92M 30.00M -159.00K
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -742.00K 5.34M 3.70M -12.69M

LGND Ligand Pharmaceuticals Inc

Analysts Ratings for LGND

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 5 4 4
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

LGND Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs